This spring, I spoke at Reuters Pharma USA 2024 with Voters for Cures champion Terry Uhl to discuss the regulatory hurdles hindering the development of new, lifesaving medicines.
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes.
This spring, I spoke at Reuters Pharma USA 2024 with Voters for Cures champion Terry Uhl to discuss the regulatory hurdles hindering the development of new, lifesaving medicines. We also examined how these treatments improve patient outcomes and reduce the cost of chronic disease, one of the biggest health care challenges patients face today.
Here are my takeaways from the discussion:
Advances in prevention and treatment could transform the lives of many patients and lower costs for the health care system.
The Inflation Reduction Act and the Biden Administration’s march-in framework weaken the strong IP protections in the United States and threaten its world-leading innovation ecosystem.
The federal government’s failure to hold PBMs accountable will further harm access to treatments and medicines for several chronic diseases.
Read more about what we’re doing to ensure that every patient can access the treatments they need here.
